SLDB
Solid Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.25
−1.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 8.1M |
| Cost of Revenue | 395.0K | 1.6M | 2.5M | 2.6M | — |
| Gross Profit | (395.0K) | (1.6M) | (2.5M) | (2.6M) | 8.1M |
| Operating Expenses | |||||
| R&D Expense | 167.4M | 140.3M | 96.4M | 76.6M | 78.4M |
| SG&A Expense | 44.8M | 38.9M | 33.3M | 27.8M | 28.9M |
| General & Admin Expense | 44.8M | 38.9M | 33.3M | 27.8M | 28.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (395.0K) | (1.6M) | (2.5M) | (2.6M) | 7.2M |
| Total Operating Expenses | 211.8M | 177.6M | 127.3M | 101.7M | 114.5M |
| Cost and Expenses | 212.2M | 179.2M | 129.7M | 104.3M | 114.5M |
| Operating Income (EBIT) | (212.2M) | (179.2M) | (129.7M) | (104.3M) | (106.5M) |
| Non-Operating | |||||
| Interest Income | 9.9M | 9.9M | 9.5M | 7.1M | 2.6M |
| Interest Expense | — | — | 340.0K | — | — |
| Net Interest Income | 9.9M | 9.9M | 9.1M | 7.1M | 2.6M |
| Other Non-Op Income/Expense | 5.1M | 4.9M | 5.0M | 8.3M | 20.5M |
| Non-Operating Income (excl Interest) | (5.1M) | (4.9M) | (5.4M) | (8.3M) | (7.2M) |
| EBT (Pre-Tax Income) | (207.1M) | (174.3M) | (124.7M) | (96.0M) | (86.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (207.1M) | (174.3M) | (124.7M) | (96.0M) | (86.0M) |
| Earnings from Cont. Ops | (207.1M) | (174.3M) | (124.7M) | (96.0M) | (86.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (207.1M) | (174.3M) | (124.7M) | (96.0M) | (86.0M) |
| Per Share | |||||
| Basic EPS | ($1.91) | ($1.99) | ($3.06) | ($4.83) | ($10.10) |
| Diluted EPS | ($1.91) | ($1.99) | ($3.06) | ($4.83) | ($10.10) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.95 |
| Shares | |||||
| Basic Shares Outstanding | 143.7M | 87.5M | 40.8M | 19.9M | 8.5M |
| Diluted Shares Outstanding | 143.7M | 87.5M | 40.8M | 19.9M | 8.5M |
| Profitability Metrics | |||||
| EBITDA | (205.1M) | (172.7M) | (121.9M) | (93.4M) | (96.9M) |
| D&A | 2.0M | 1.6M | 2.5M | 2.6M | 2.4M |
| EBIT | (207.1M) | (174.3M) | (124.4M) | (96.0M) | (99.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026